Oncimmune Regulatory News (ONC)

17 August 2016

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Andrew Millet appointed to the Board as Chief Financial Officer

Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, announces that it has appointed Andrew Millet, BA MBA, FCA as an Executive Director and Chief Financial Officer.

Andrew has held varied senior finance positions in both public and private companies for over 20 years and has broad experience in managing high growth businesses, fund raisings and corporate governance. Prior to being appointed CFO of Oncimmune, Andrew held the position of Company Secretary and since June of this year, he has been acting interim CFO. Andrew trained as an accountant with Stoy Hayward (now BDO) and is a registered auditor.

Geoffrey Hamilton-Fairley, CEO of Oncimmune commented: "We are delighted that Andrew has accepted the position of CFO. Having previously held the position of Company Secretary and interim CFO, he is already very familiar with the Company and I am confident he will provide solid financial guidance and support as we continue to commercialise our EarlyCDT®-Lung test and complete the final clinical validation stage of our EarlyCDT® liver and ovarian tests."

Commenting on his appointment, Andrew Millet said: "I am very pleased to accept the position of CFO and to continue to work with the Oncimmune team. I have great belief in the autoantibody tests that can detect cancer up to four years earlier than other methods and look forward to playing a part in their continued success."

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

- Full name and age: Andrew Millet (aged 48)

- Current Directorships:

• Cyber-Duck Limited

• Pinknews Media Group Limited

• Voiceserve Inc

• Wisteria Limited

• Wisteria Formations Limited

- Past Directorships (within the previous 5 years)

• Incremental Plus Limited (dormant - dissolved 14/10/2014)

• Choices 4 All

• Globex Data Limited (dormant - dissolved 24/4/2012)

• Web 2 Innovation Limited (dormant - dissolved 23/10/2012)

• Adaptive Affinity Limited

• Mediteranean Energy & Petroleum Company Limited (dissolved 19/4/2016)

• Activinstinct Limited

• Azappy Limited

• Unquoted Capital Limited (dissolved 10/3/2015)

• Credit Rating Office Limited

No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules for Companies.

About Oncimmune

Oncimmune is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 145,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,000 high-risk smokers. EarlyCDT® tests for liver and ovarian cancer are in development.

Oncimmune, headquartered in Nottingham, United Kingdom with testing facilities in the US, joined AIM in May 2016 under the ticker ONC.L. For more information visit www.oncimmune.com

For further information:

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

contact@oncimmune.co.uk

Zeus Capital Limited (Nominated Adviser and Broker)

Phil Walker, Giles Balleny, Dominic Wilson

+44 (0) 203 829 5000

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville

oncimmune@consilium-comms.com

+44 (0) 20 3709 5708